Dry eye growth is carrying the rebuild
- Q1 2026 was a proof point for margin expansion, with adjusted EBITDA up 59% year over year and margin up about 500 basis points.
- The dry eye drug pair, MIEBO and XIIDRA, drove the upside with revenue growth of 33% and 30% year over year.
- Vision Care is still the largest segment, with $711 million of Q1 2026 revenue out of $1.244 billion total company revenue.
- Surgical is the main watch item after only 1% constant-currency growth in Q1, despite premium IOL strength.
- The stock still needs proof that drug growth, Surgical recovery, and pricing can all work at the same time.
Dry eye proves the leverage case
Bausch + Lomb had a strong Q1 2026. Revenue grew 9% year over year to $1.244 billion, and adjusted EBITDA rose 59%. That matters because the bull case is that the company can grow while turning more of each new sales dollar into profit.
The key driver is dry eye. MIEBO had $76 million of Q1 revenue, up 33% year over year. XIIDRA had $87 million, up 30%. Management now says this franchise has moved from launch phase to growth phase, which means selling costs should weigh less as sales scale.
The bear case starts with Surgical. Segment revenue was $228 million in Q1, up 7% as reported but only 1% in constant currency. Management blamed weather, some reimbursement pressure, a hard prior-year comparison, and a rebuild of the U.S. field force. Those may be temporary, but investors need to see better growth in Q2 and Q3.
The setup is balanced. BLCO is showing real profit leverage, and management raised 2026 adjusted EBITDA guidance to $1.01 billion to $1.06 billion. But the company has to prove XIIDRA can hold double-digit growth, Surgical can recover, and gross-to-net pressure, which means rebates and discounts taken off gross drug sales, does not eat too much of the upside.
Three ways to sell eye care
Bausch + Lomb is a full eye health company. It makes and sells about 400 products across around 100 countries. The product range runs from contact lenses and over-the-counter drops to prescription eye drugs and surgical equipment.
The model has three parts. Vision Care brings scale through contact lenses, lens care, Lumify, Blink, and PreserVision. Pharmaceuticals can grow faster when branded drugs like MIEBO and XIIDRA gain share. Surgical sells devices and consumables used in cataract and retinal procedures.
Management added a fourth operating pillar called financial excellence. In plain English, that means cost control, better sales execution, and higher margins. Q1 gave early proof, especially in Pharmaceuticals, where segment profit margin improved sharply as MIEBO and XIIDRA moved beyond their highest-spend launch period.
The model can break if drugs lose exclusivity, rebates rise faster than sales, supply issues hit key products, or Surgical sales reps do not regain momentum. The parent company, Bausch Health, also still holds a majority stake, so separation or sale timing remains part of the story.
The portfolio that matters most
MIEBO and XIIDRA
These are the core dry eye prescription drugs. In Q1 2026, MIEBO revenue rose 33% year over year and XIIDRA revenue rose 30%.
Contact lenses and lens care
This includes Biotrue ONEday, INFUSE, ULTRA, Biotrue, and Renu. It gives Vision Care a large recurring base because people keep buying lenses and solutions.
Lumify, Blink, and PreserVision
These are consumer eye care products sold without a prescription. Q1 strength came from the consumer dry eye portfolio and Lumify, and the company began shipping PreserVision AREDS 3 and preservative-free Blink Triple Care.
LUMIFY NXT
The company filed a new drug application, or NDA, for LUMIFY NXT in Q1 2026. If approved, it could extend the Lumify franchise.
enVista and premium IOLs
IOLs are artificial lenses used in cataract surgery. Premium IOLs grew 27% in Q1 2026, even while the broader Surgical segment was soft.
seeLYRA surgical system
The company completed a CE Mark submission for seeLYRA in Q1 2026. A CE Mark can allow sale in Europe if regulators clear the product.
Vyzulta, Lotemax, and other prescription drugs
These drugs help round out the Pharmaceuticals segment across glaucoma, inflammation, and other eye conditions. The risk is that older products can face generic competition.
Q1 mix shows Vision Care leads
Segment mix uses Q1 2026 revenue: Vision Care $711 million, Pharmaceuticals $305 million, and Surgical $228 million. The total was $1.244 billion, so Vision Care is still the largest source of sales.
What could go wrong
Surgical rebuild stalls
High impact · Medium oddsSurgical grew only 1% in constant currency in Q1 2026. Management says weather, reimbursement pressure, a tough comparison, and a U.S. field force rebuild caused the shortfall. If the rebuild takes longer than planned, the segment could miss tougher comparisons later in 2026.
Dry eye growth fades too fast
High impact · Medium oddsMIEBO and XIIDRA carried the quarter, with Q1 revenue growth of 33% and 30%. That growth may slow as the year gets harder to compare against. XIIDRA is now expected to settle into low double-digit growth, so a larger slowdown would hurt the margin story.
Rebates eat the drug upside
Medium impact · Medium oddsGross-to-net pressure means discounts, rebates, and fees reduce reported drug sales. The 2025 filings showed higher rebates from the dry eye portfolio, including XIIDRA and MIEBO. If rebates keep rising, strong demand may not fully show up in revenue or profit.
Patent and generic pressure
High impact · Medium oddsThe company faces generic competition and loss of exclusivity risk across its drug portfolio. It also has patent infringement proceedings tied to major products such as Lumify and PreserVision. A bad ruling or new generic launch could cut sales or force higher legal and marketing spend.
Bausch Health overhang remains
Medium impact · Medium oddsBausch Health still owns a majority stake in Bausch + Lomb. That creates uncertainty around the timing and form of a full separation, and it may also affect any potential sale of the company. Investors may apply a discount until ownership is clearer.
Reimbursement and supply shocks
Medium impact · Medium oddsThe One Big Beautiful Bill Act may lower reimbursements for drugs covered by government health programs. The company also faces global supply chain and geopolitical risks. The enVista IOL recall is considered resolved, but it shows how product disruptions can hit a segment quickly.